Neurocrine Operating Margin from 2010 to 2024

NBIX Stock  USD 142.89  0.14  0.1%   
Neurocrine Biosciences Operating Profit Margin yearly trend continues to be fairly stable with very little volatility. Operating Profit Margin is likely to outpace its year average in 2024.
Check Neurocrine Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Neurocrine main balance sheet or income statement drivers, such as Depreciation And Amortization of 22.4 M, Interest Expense of 7.4 M or Selling General Administrative of 894.2 M, as well as many exotic indicators such as Price To Sales Ratio of 6.48, Dividend Yield of 0.0 or PTB Ratio of 6.13. Neurocrine financial statements analysis is a perfect complement when working with Neurocrine Biosciences Valuation or Volatility modules.
  
This module can also supplement Neurocrine Biosciences' financial leverage analysis and stock options assessment as well as various Neurocrine Biosciences Technical models . Check out the analysis of Neurocrine Biosciences Correlation against competitors.
For more information on how to buy Neurocrine Stock please use our How to Invest in Neurocrine Biosciences guide.

Latest Neurocrine Biosciences' Operating Margin Growth Pattern

Below is the plot of the Operating Profit Margin of Neurocrine Biosciences over the last few years. It is Neurocrine Biosciences' Operating Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Neurocrine Biosciences' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 0.29 %10 Years Trend
Slightly volatile
   Operating Profit Margin   
       Timeline  

Neurocrine Operating Margin Regression Statistics

Arithmetic Mean(2.35)
Coefficient Of Variation(212.42)
Mean Deviation3.60
Median0.13
Standard Deviation5.00
Sample Variance24.98
Range17.457
R-Value0.33
Mean Square Error24.00
R-Squared0.11
Significance0.23
Slope0.37
Total Sum of Squares349.70

Neurocrine Operating Margin History

2024 0.14
2023 0.13
2021 0.17
2020 0.3
2019 0.28
2018 0.0818
2017 -0.81

About Neurocrine Biosciences Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Neurocrine Biosciences income statement, its balance sheet, and the statement of cash flows. Neurocrine Biosciences investors use historical funamental indicators, such as Neurocrine Biosciences's Operating Margin, to determine how well the company is positioned to perform in the future. Although Neurocrine Biosciences investors may use each financial statement separately, they are all related. The changes in Neurocrine Biosciences's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Neurocrine Biosciences's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Neurocrine Biosciences Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Neurocrine Biosciences. Please read more on our technical analysis and fundamental analysis pages.
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California. Neurocrine Bioscienc operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 1150 people.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Neurocrine Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Neurocrine Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Neurocrine Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Neurocrine Biosciences Stock:
Check out the analysis of Neurocrine Biosciences Correlation against competitors.
For more information on how to buy Neurocrine Stock please use our How to Invest in Neurocrine Biosciences guide.
You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..

Complementary Tools for Neurocrine Stock analysis

When running Neurocrine Biosciences' price analysis, check to measure Neurocrine Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurocrine Biosciences is operating at the current time. Most of Neurocrine Biosciences' value examination focuses on studying past and present price action to predict the probability of Neurocrine Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurocrine Biosciences' price. Additionally, you may evaluate how the addition of Neurocrine Biosciences to your portfolios can decrease your overall portfolio volatility.
Bonds Directory
Find actively traded corporate debentures issued by US companies
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Is Neurocrine Biosciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurocrine Biosciences. If investors know Neurocrine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurocrine Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.648
Earnings Share
2.47
Revenue Per Share
19.315
Quarterly Revenue Growth
0.25
Return On Assets
0.0878
The market value of Neurocrine Biosciences is measured differently than its book value, which is the value of Neurocrine that is recorded on the company's balance sheet. Investors also form their own opinion of Neurocrine Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Neurocrine Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurocrine Biosciences' market value can be influenced by many factors that don't directly affect Neurocrine Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neurocrine Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neurocrine Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurocrine Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.